Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

Phase 2 Withdrawn Premier Research Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab

NaSingle-groupOpen-labelOther

Summary

This is a Phase IIb multicenter, open-label, non-comparative trial of continuous daily oral 10 mg of ulipristal acetate (UPA) to evaluate its contraceptive efficacy as the primary method of contraception.

Timeline

Start: 2020-12
Primary completion: 2022-01
Completion: 2022-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ulipristal Acetate	Unknown	10 mg	Oral

Indications

No indication recorded.